Payment overview · 2025
General Payments
$819.76
45 reported records · 19 companies
Healthcare provider profile · identity verified
Scott L Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · PLEASANT GROVE, UT · NPI 1336257617
Verified facts
What the public records show
CMS Open Payments records show Scott L Smith, MD received $819.76 in general payments during 2025 across 45 reported records.
ABBVIE INC. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $279.07 | 34.0% | 15 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.12 | 10.5% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.54 | 9.1% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $67.48 | 8.2% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.43 | 4.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.44 | 3.6% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.75 | 3.5% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $22.49 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.32 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.86 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.28 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.44 | 2.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $18.81 | 2.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.75 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.38 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.92 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.42 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.65 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.61 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $819.76 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $153.75 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.21 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $125.32 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $86.12 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $74.54 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $67.48 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Zolpidem Tartrate | Zolpidem Tartrate | 475 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 425 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 419 | 122 |
| Metformin Hcl | Metformin Hcl | 276 | 82 |
| Omeprazole | Omeprazole | 268 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 70 |
| Gabapentin | Gabapentin | 238 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 237 | 47 |
| Losartan Potassium | Losartan Potassium | 228 | 61 |
| Celecoxib | Celecoxib | 219 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 62 |
| Tramadol Hcl | Tramadol Hcl | 210 | 43 |
| Potassium Chloride | Potassium Chloride | 206 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 42 |
| Trazodone Hcl | Trazodone Hcl | 160 | 36 |
| Cefuroxime | Cefuroxime Axetil | 155 | 93 |
| Furosemide | Furosemide | 142 | 54 |
| Lorazepam | Lorazepam | 127 | 29 |
| Meloxicam | Meloxicam | 121 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 34 |
| Eliquis | Apixaban | 116 | 25 |
| Azithromycin | Azithromycin | 114 | 66 |
| Ondansetron Odt | Ondansetron | 110 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 30 |
| Lisinopril | Lisinopril | 105 | 31 |
| Alprazolam | Alprazolam | 100 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 99 | 39 |
| Sertraline Hcl | Sertraline Hcl | 98 | 27 |
| Clonazepam | Clonazepam | 97 | 17 |
| Mounjaro | Tirzepatide | 96 | 21 |
| Simvastatin | Simvastatin | 95 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 31 |
| Finasteride | Finasteride | 89 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 27 |
| Jardiance | Empagliflozin | 83 | 22 |
| Acyclovir | Acyclovir | 82 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 20 |
| Allopurinol | Allopurinol | 74 | 23 |
| Cephalexin | Cephalexin | 70 | 49 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 14 |
| Memantine Hcl | Memantine Hcl | 62 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 20 |
| Methylprednisolone | Methylprednisolone | 59 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 30 |
| Alendronate Sodium | Alendronate Sodium | 57 | 18 |
| Estradiol | Estradiol | 57 | 19 |
| Fluconazole | Fluconazole | 56 | 32 |
| Mupirocin | Mupirocin | 56 | 35 |
| Carisoprodol | Carisoprodol | 55 | suppressed |
| Trulicity | Dulaglutide | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 49 | 16 |
| Torsemide | Torsemide | 47 | 18 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 13 |
| Glimepiride | Glimepiride | 43 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 24 |
| Carvedilol | Carvedilol | 40 | 15 |
| Pregabalin | Pregabalin | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Naproxen | Naproxen | 38 | 17 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 12 |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 16 |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 18 |
| Xtampza Er | Oxycodone Myristate | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 13 |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 14 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Temazepam | Temazepam | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 14 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $819.76 · 45 records | ABBVIE INC. | AREXVY, Dexcom G6 Transmitter, Doc Band, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, NEUROSTAR TMS THERAPY SYSTEM, QULIPTA, Qelbree, SAPIEN 3 Ultra RESILIA, SHINGRIX, UBRELVY, VENASEAL, VOQUEZNA, VRAYLAR, WATCHMAN FLX, YUPELRI, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error